Biocon has inaugurated a world class facility for manufacturing
new generation, patient-friendly devices for its insulins portfolio in
Bangalore. The 100,000 square feet, state-of-the-art new devices facility is an
outcome of Biocon’s commitment to ‘Make in India for the World’ which is aligned with
the Government’s ‘Make in India’ vision to transform the country into a global
manufacturing hub. The facility will enable Biocon to leverage the country’s
manufacturing expertise to develop world-class delivery devices for people with
diabetes in India and other parts of the world.
The
facility was inaugurated by Amitabh Kant, Secretary, Department of Industrial
Promotion and Policy, Government of India along with Kaushik Mukherjee, Chief
Secretary, Government of Karnataka and V Manjula, Secretary, IT, BT and
S&T, Government of Karnataka. Kant also launched Basalog One, a high-end,
ready-to-use insulin glargine disposable pen for better blood sugar management
for people with diabetes, manufactured in this facility.
Biocon’s
Basalog One, a long acting basal insulin glargine presented as an innovative,
pre-filled pen, is the first product to roll out of this facility. Basalog One
as a ‘once a day’ product is convenient to administer and almost painless,
which will enable better patient compliance and help patients manage their
blood sugar levels most effectively. The pen is light weight, easy to carry and
disposable.
Kant said,
“I want to congratulate Biocon on the inauguration of this new facility and the
launch of Basalog One. This product, made in such a top class facility, will
make a radical difference in the lives of many millions of diabetes patients
globally. It’s a huge step forward for such a product to be ‘Made in India’. I
am proud of the Biocon team for the focus they have exhibited in making this
dream a success.”
Kiran Mazumdar-Shaw said, “Our aim is to
provide insulin products to at least one in five insulin-dependent diabetes
patients, anywhere in the world. This new devices facility is a key milestone
in our journey towards that goal. It will enable us to not only fulfil our
commitment to ‘Make in India for the World’ but also deliver on the promise of
‘Affordable Access to Healthcare for All’. Through our product Basalog One, we
will be providing a high–end patient-friendly basal insulin glargine pen in
India first and global markets, subsequently.”
Dr Arun Chandavarkar, Chief Executive Officer
and Jt Managing Director, Biocon, said, “India has the potential to become the
next global manufacturing hub in biomedical devices and at Biocon, we are
committed to explore this potential. As we expand our reach in global markets
to provide access to affordable diabetes therapy options, Basalog One will form
a significant part of our offering to people with diabetes in different parts
of the world.”
Basalog
One is built at Biocon’s new devices facility using a 3 ml cartridge of 100IU
insulin glargine manufactured by Biocon. The active drug substance and the drug
product for the pen is being manufactured by Biocon in India. Biocon’s Basalog
One is a first-of-its-kind, disposable insulin glargine pen, designed
internationally and built locally for the global markets.
Source : http://www.financialexpress.com/article/pharma/latest-updates/biocon-inaugurates-devices-facility-for-insulin-portfolio-in-bangalore/136425/
No comments:
Post a Comment